Timothy Yu, MD, PhD

Mukesh Jain, MD

When Jonathan Stamler asked Mukesh Jain to serve as Scientific Director in 2013 (later he became Chief Scientific Officer), Mukesh seized the opportunity to be in on the ground floor of managing operations for Harrington Discovery Institute. Mukesh, an internationally respected physician-scientist who joined University Hospitals and Case Western Reserve University School of Medicine faculty in 2006, assumed responsibilities for recruiting faculty, overseeing Harrington Scholar programs and the annual Scientific Symposium, as well as the selection of the annual Harrington Prize recipient.

Becca Braun

A successful tech entrepreneur, Becca had led many new ventures including co-founding and serving as COO of JumpStart, a nationally recognized venture development firm in Cleveland. When Jonathan Stamler told her, “We have a great opportunity here, but we have a lot of work to do,” she knew exactly what was required. She proceeded to systematically help create and ‘productize’ the Harrington Scholar programs and establish important processes, that are in use today. Becca continues to act as staff liaison to the Scientific Advisory Board.

Perry Molinoff, MD

Dr. Perry Molinoff first heard about Harrington Discovery Institute and The Harrington Project over dinner one evening with his neighbor in Philadelphia, David U’Prichard. Soon after Perry stepped in and helped launch the Innovation Support Center (now the Therapeutics Development Center), which has become the “secret sauce” that sets the Harrington model apart. He further expanded the model by recognizing that in many cases the initial grant funds awarded were not enough to reach meaningful milestones. As a result he worked with Jonathan Stamler to establish a process for scholars to apply for supplemental funding, now called Stage 2 funding.

John Rice, PhD

“Would you come over and talk to Jonathan about your background?” This was the question from BioMotiv’s Baiju Shah that led to John Rice’s involvement with Harrington Discovery Institute. Shortly after Baiju posed the question, John found himself across the table from Jonathan discussing the Innovation Support Center (now the Therapeutics Development Center), and the need for an advisory group that would oversee post-award investment decisions. A seasoned leader and advisor in med-tech, life sciences, and pharma, John was well-suited to chair the new Investment Advisory Board.